Related Experiment Video
Updated: Jul 6, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
CanCHD Study of Hematopoietic Cancers in Children With and Without Genetic Syndromes
Mohammad Sazzad Hasan1, Elie Ganni2, Aihua Liu2
1Department of Epidemiology, Biostatistics and Occupational Health McGill University Montreal Quebec Canada.
Insights
Children with congenital heart disease (CHD) and genetic syndromes face a significantly higher risk of developing hematopoietic cancer (HC). This study highlights the importance of considering genetic factors in cancer surveillance for these children.
Area of Science:
- Pediatric Oncology
- Cardiology
- Genetics
- Epidemiology
Background:
- Congenital heart disease (CHD) and cancer may share common underlying genetic pathways.
- Reliable risk estimates for hematopoietic cancer (HC) in children with CHD are limited.
- Genetic syndromes are known to increase susceptibility to various diseases.
Purpose of the Study:
- To quantify the risk of hematopoietic cancer (HC) in children with congenital heart disease (CHD).
- To investigate the influence of genetic syndromes on HC risk within this population.
- To provide data for improved cancer surveillance strategies.
Main Methods:
- Utilized Canadian CHD and Canadian Cancer Registry (CCR) data (1999-2017).
- Calculated standardized incidence ratios (SIR) comparing HC incidence in children with CHD to the general pediatric population.
- Employed Kaplan-Meier curves to estimate cumulative HC incidence with death as a competing risk.
Main Results:
- A total of 143,794 children with CHD were analyzed.
- Children with known genetic syndromes had a substantially higher risk of HC (SIR 13.4).
- Cumulative HC incidence was 2.44% in children with syndromes versus 0.79% without.
Conclusions:
- Known genetic syndromes are a significant predictor of hematopoietic cancer in children with CHD.
- This finding is crucial for developing risk-stratified cancer surveillance policies.
- Early childhood acute myeloid leukemia showed a higher incidence than acute lymphoblastic leukemia.
Background:
Individuals with genetic syndromes can manifest both congenital heart disease (CHD) and cancer attributable to possible common underlying pathways. To date, reliable risk estimates of hematopoietic cancer (HC) among children with CHD based on large population-based data remain scant. This study sought to quantify the risk of HC by the presence of genetic syndrome among children with CHD.
Methods And Results:
Data sources were the Canadian CHD database, a nationwide database on CHD (1999-2017), and the CCR (Canadian Cancer Registry). Standardized incidence ratios were calculated for comparing HC incidences in children with CHD with the general pediatric population. A modified Kaplan-Meier curve was used to estimate the cumulative incidence of HC with death as a competing risk. A total of 143 794 children (aged 0-17 years) with CHD were followed up from birth to age 18 years for 1 314 603 person-years. Of them, 8.6% had genetic syndromes, and 898 HC cases were observed. Children with known syndromes had a substantially higher risk of incident HC than the general pediatric population (standardized incidence ratio, 13.4 [95% CI, 11.7-15.1]). The cumulative incidence of HC was 2.44% (95% CI, 2.11-2.76) among children with a syndrome and 0.79% (95% CI, 0.72-0.87) among children without a syndrome. Acute myeloid leukemia had a higher cumulative incidence during early childhood than acute lymphoblastic leukemia.
Conclusions:
This is the first large population-based analysis documenting that known genetic syndromes in children with CHD are a significant predictor of HC. The finding could be essential in informing risk-stratified policy recommendations for cancer surveillance in children with CHD.
More Related Videos
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Hematopoiesis
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Multipotency of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

